2021 AACC Annual Scientific Meeting to Require Both Proof of COVID-19 Vaccination and Negative Test from All In-Person Attendees
|
By LabMedica International staff writers Posted on 31 Aug 2021 |

Illustration
The 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting & Clinical Lab Expo will be a live event with new location and dates, backed by plans to make the meeting a safe and productive one amidst the flare up in the COVID-19 pandemic.
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
This year's AACC Annual Scientific Meeting, held in partnership with the Canadian Society of Clinical Chemists, has moved from Anaheim to Atlanta due to stringent COVID-19 lockdown requirements in California, and the meeting dates have also moved by one week to September 26-30. In his latest email, AACC 2021 President Dr. Stephen Master, PhD, had outlined the extensive health and safety planning to make this year’s AACC Annual Scientific Meeting and Clinical Lab Expo in Atlanta a safe and productive in-person meeting. In order to ensure the safety of all attendees, the email clearly stated that unvaccinated people would not be permitted into the conference and expo campus without a current, negative SARS-CoV-2 antigen test or verified proof of vaccination.
As per its latest update, AACC now requires all meeting participants to be vaccinated, and for all meeting participants to have received a negative PCR or antigen COVID-19 test within 72 hours of arriving at the convention center. Proof of COVID-19 vaccination AND proof of a negative PCR or antigen coronavirus test will be required for in-person attendees of the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Individuals who are unable to provide both of these things will not be permitted to enter the meeting and antibody test results will not be accepted.
Additionally, mask policies will be in place and strictly enforced. All persons within the AACC meeting campus must wear a face mask covering their nose and mouth at all times they are indoors. Moreover, detailed meeting logistics and design have been laid down to prevent crowding and disperse crowding at the event, and additional measures may be taken if required. Signage will be used to encourage social distancing, plexiglass separations will be placed at points of sale, and educational session times will be staggered to reduce the number of attendees in common areas.
“Our plans to hold a safe and productive in-person meeting in Atlanta have not changed,” wrote Dr. Stephen Master. “The meeting is on, and it will be safe.”
“I encourage you to check out the conference program if you haven’t already. And I look forward to seeing many of you in Atlanta next month,” he added.
Related Links:
American Association for Clinical Chemistry
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform
Channels
Clinical Chemistry
view channel
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more
New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
Oral squamous cell carcinoma can be difficult to triage at the point of care, resulting in frequent biopsies of lesions that ultimately prove benign. Limited access to pathology services in many communities... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more






 Assay.jpg)


